A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent Temozolomide Resistant Glioblastoma: An NRG Oncology RTOG Group Study

This study tested the hypothesis that ABT-888 (velparib), a poly (ADP-ribose) polymerase (PARP) inhibitor, can modulate temozolomide (TMZ) resistance in recurrent TMZ refractory glioblastoma patients. The combination regimen (TMZ/ABT-888) was tested using 2 randomized schedules (5 versus 21 days), w...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Neurooncol
Autori principali: Robins, H Ian, Zhang, Peixin, Gilbert, Mark R, Chakravarti, Arnab, de Groot, John F, Grimm, Sean A, Wang, Fen, Lieberman, Frank S, Krauze, Andra, Trotti, Andy M, Mohile, Nimish, Kee, Andrew Y J, Colman, Howard, Cavaliere, Robert, Kesari, Santosh, Chmura, Steven J, Mehta, Minesh
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4720526/
https://ncbi.nlm.nih.gov/pubmed/26508094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-015-1966-z
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi